You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AK104

Showing 1 - 25 of 622
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AK104 Combined With I-125 Brachytherapy for Recurrent or

Not yet recruiting
  • Cervical Cancer
  • Iodine-125 particle brachytherapy
  • AK104
  • (no location specified)
Sep 25, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial (Cadonilimab, Carboplatin, Cisplatin)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • (no location specified)
Oct 7, 2023

Advanced Malignant Tumors Trial (AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion)

Not yet recruiting
  • Advanced Malignant Tumors
  • AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
  • (no location specified)
May 11, 2023

Advanced Non-small-cell Lung Cancer Trial in Shanghai (AK112, AK104, caboplatin)

Not yet recruiting
  • Advanced Non-small-cell Lung Cancer
  • Shanghai, China
    Shanghai Pulmonary Hospital
Jun 6, 2023

Locally Advanced Rectal Cancer Trial (AK104 injection, TME surgery, Capecitabine)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • AK104 injection
  • +3 more
  • (no location specified)
Apr 4, 2023

Locally Advanced Rectal Cancer Trial in Guangzhou (AK104, Capecitabine, Neoadjuvant Radiotherapy)

Not yet recruiting
  • Locally Advanced Rectal Cancer
  • AK104
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 5, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Nasopharyngeal Carcinoma Trial in Wuhan (Cadonilimab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Mar 27, 2023

Muscle Invasive Bladder Carcinoma Trial in Beijing (RC48-ADC, AK104)

Recruiting
  • Muscle Invasive Bladder Carcinoma
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Oct 6, 2023

Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)

Recruiting
  • Gastric Cancer
  • AK104
  • +3 more
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 7, 2023

Esophageal Squamous Cell Carcinoma Trial in Anyang, Zhengzhou (AK104, nab-paclitaxel, carboplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • AK104, nab-paclitaxel, carboplatin
  • Anyang, Henan, China
  • +1 more
Jun 1, 2023

Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma Trial in Chengdu (AK104, Axitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • +3 more
  • Chengdu, Sichuan, China
    West China Hospital
Apr 10, 2023

Solid Tumor, Adult Trial in Tianjin (AK119, AK104)

Recruiting
  • Solid Tumor, Adult
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insitute & Hospital
Dec 28, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Healthy Male Subjects Trial (AK104 (before the change), AK104 (after the change))

Not yet recruiting
  • Healthy Male Subjects
  • AK104 (before the change)
  • AK104 (after the change)
  • (no location specified)
Sep 26, 2022

Vulvar Cancer Trial in China (AK104)

Not yet recruiting
  • Vulvar Cancer
  • AK104
  • Fuzhou, Fujian, China
  • +5 more
Jun 27, 2023

Bladder Cancer Trial in Tianjin (Cadonilimab)

Recruiting
  • Bladder Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 23, 2023

Pancreatic Cancer Trial in China (AK104, Gemcitabine, Nab-Paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • AK104
  • +2 more
  • Beijing, Beijing, China
  • +6 more
May 5, 2023

Esophageal Squamous Cell Carcinoma Trial (AK104)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • AK104
  • (no location specified)
Oct 25, 2022

Advanced Solid Tumor Trial in Hangzhou (AK109+AK104)

Recruiting
  • Advanced Solid Tumor
  • Hangzhou, Zhejiang, China
    First affliated hospital of Zhejiang University
Oct 17, 2022

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)

Active, not recruiting
  • Hepatocellular Carcinoma
  • AK104 lenvatinib
  • AK104
  • Hangzhou, Zhejiang, China
    The first affilited hospital zhejiang university school of medci
Oct 17, 2022

NSCLC Trial in Changsha (AK104+anlotinib)

Active, not recruiting
  • NSCLC
  • Changsha, Hunan, China
    Hunan cancer hospital
May 18, 2022

Carcinomas, Cervix Cancer, Cervical Cancer Trial in Houston (AK104)

Recruiting
  • Carcinomas
  • +2 more
  • AK104
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022